Opportunity
Saskatchewan Tenders #ACAN-SHA20260901
Award for Rapid Multiplex PCR Panel Testing Equipment and Services for Sepsis and Meningitis-Encephalitis
Posted
September 01, 2026
Respond By
September 28, 2026
Identifier
ACAN-SHA20260901
NAICS
541380, 325413
The Saskatchewan Health Authority (SHA) is awarding a seven-year contract for rapid multiplex PCR panel testing solutions for Sepsis and Meningitis-Encephalitis across multiple provincial laboratory sites. - Government Buyer: - Saskatchewan Health Authority (SHA) - OEM Highlight: - BioMerieux Canada Inc. (FilmArray Torch System) - Products and Services Requested: - Rapid multiplex PCR panel testing equipment (FilmArray Torch System) - Associated consumables and reagents - Testing services, including QC materials, training, and support - Technical and Performance Requirements: - Equipment must be Health Canada approved - Capable of detecting a comprehensive range of bacterial, yeast, viral targets, and antimicrobial resistance genes - Modular design to fit limited laboratory space - Rapid turnaround time (≤3 hours) - Automated QC monitoring and proficiency test materials - Integration with Laboratory Information System (SoftLab) - Usable by non-MLT staff (training provided) - Notable Details: - The FilmArray Torch System is already in use at several sites - Other suppliers may submit statements of capabilities if they can meet all requirements - No specific part numbers or quantities provided
Description
The Saskatchewan Health Authority (SHA) intends to award a seven-year contract for equipment, services, and consumables for Rapid Multiplex Syndromic Panel testing for Sepsis and Meningitis Encephalitis at multiple laboratory sites in Saskatchewan. The contract is currently intended for BioMerieux Canada Inc., but other suppliers may submit statements of capabilities to demonstrate they meet the requirements. The equipment must support testing at various sites and provide rapid turnaround times with a small footprint suitable for limited lab space. The testing panels must be Health Canada approved and capable of detecting a range of bacterial, yeast, and viral targets, including antimicrobial resistance genes.